AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that a presentation will be made at the 2015 Annual Meeting of the American Society of Anesthesiologists (Anesthesiology 2015) …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that a presentation will be made at the annual European Society of Emergency Medicine (EuSEM) meeting to be held …
Cowen’s healthcare analyst Boris Peaker weighed in today with a few insights on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), after the company provided a regulatory update on Zalviso, which …
In a research report issued today, Roth Capital analyst Michael Higgins reiterated a Buy rating on shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) while raising the …
In a research report released Tuesday, Roth Capital analyst Michael Higgins reiterated a Buy rating on shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), while raising …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that the European Commission (EC) has approved Zalviso™ (15 micrograms sufentanil sublingual tablets) for the management of acute moderate-to-severe …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough …
